<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Cardiac manifestations in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Cardiac manifestations in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Cardiac manifestations in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alida LP Caforio, MD, PhD, FESC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donna Mancini, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1219856872"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously referred to as 2019-nCoV). Patients with COVID-19 typically present with symptoms and signs of respiratory tract infection, but cardiac manifestations, including signs of myocardial injury, are common. This topic will discuss cardiac manifestations in adults with COVID-19.</p><p>Cardiac evaluation and management in adults with COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults"</a>.)</p><p>Some specific cardiac issues in adults with COVID-19 are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127551.html" rel="external">"COVID-19: Arrhythmias and conduction system disease"</a>.)</p><p></p><p>Other clinical aspects of COVID-19 are discussed separately, including these and other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Potential association between mRNA vaccines to prevent SARS-CoV-2 infection and myocarditis. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Myocarditis'</a>.)</p><p></p><p class="headingAnchor" id="H4132805513"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Patients with COVID-19 commonly have manifestations of heart disease, including signs of myocardial injury (see <a class="local">'Troponin'</a> below), but the causes of these findings have not been established.</p><p class="headingAnchor" id="H3028899669"><span class="h2">Possible causes</span><span class="headingEndMark"> — </span>Possible causes of myocardial injury in patients with COVID-19 include hypoxic injury; stress (takotsubo) cardiomyopathy [<a href="#rid1">1,2</a>]; ischemic injury caused by cardiac microvascular dysfunction, small vessel cardiac vasculitis [<a href="#rid3">3</a>], endotheliitis [<a href="#rid4">4</a>], or epicardial coronary artery disease (with plaque rupture or demand ischemia); right heart strain (acute cor pulmonale, with causes including pulmonary embolism [<a href="#rid5">5-9</a>], adult respiratory distress syndrome [<a href="#rid10">10</a>], and pneumonia); myocarditis [<a href="#rid11">11,12</a>]; and systemic inflammatory response syndrome (cytokine storm) [<a href="#rid13">13-16</a>]. However, the contribution of each of these causes to myocardial injury and adverse cardiovascular outcomes in this setting has not been determined. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a> and  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a> and  <a class="medical medical_review" href="/d/html/1469.html" rel="external">"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome"</a> and  <a class="medical medical_review" href="/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Troponin'</a>.)</p><p class="headingAnchor" id="H683019438"><span class="h2">Impact of preexisting cardiovascular disease</span><span class="headingEndMark"> — </span>Symptoms and signs of heart disease in a patient with COVID-19 may result from an acute disease process, from hemodynamic demands in the setting of chronic (preexisting) heart disease, or may be caused by an acute exacerbation of chronic disease.</p><p>As discussed separately, there is substantial evidence of association between preexisting cardiovascular disease (such as hypertension and coronary artery disease) and the risk and severity of COVID-19 infection [<a href="#rid17">17</a>]. The causes of this association have not been determined. Proposed mechanisms include impaired physiologic reserve (cardiovascular and pulmonary), impaired immune response, augmented inflammatory response, vulnerability to SARS-CoV-2-induced endothelial dysfunction, and effects mediated by the angiotensin-converting enzyme 2 receptor [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues", section on 'Association between baseline CVD and COVID-19'</a>.)</p><p class="headingAnchor" id="H1780220865"><span class="h1">ACUTE CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with acute COVID-19 may present with a broad spectrum of clinical cardiac presentations: some patients manifest no clinical evidence of heart disease, some have no symptoms of heart disease but have cardiac test abnormalities (such as serum cardiac troponin elevation, asymptomatic cardiac arrhythmias, or abnormalities on cardiac imaging), and some have symptomatic heart disease. Cardiac complications include myocardial injury, heart failure (HF), cardiogenic shock, and cardiac arrhythmias including sudden cardiac arrest. The following sections review the spectrum of cardiac manifestations in patients with COVID-19.</p><p>Most patients with COVID-19 with abnormalities on cardiac testing have typical symptoms of COVID-19, including cough, fever, myalgia, headache, and dyspnea, as described separately. A minority of patients with COVID-19 present with symptoms that may suggest heart disease (such as palpitations [<a href="#rid19">19</a>] or chest pain [<a href="#rid20">20</a>]). These symptoms may or may not be accompanied by prior or concurrent symptoms typical of COVID-19 infection [<a href="#rid13">13,21</a>]. Symptoms such as dyspnea and chest pain may be caused by noncardiac and/or cardiac causes. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2434313323"><span class="h2">Asymptomatic heart disease</span><span class="headingEndMark"> — </span>Most patients with COVID-19 with cardiac test abnormalities (such as cardiac troponin elevation, electrocardiographic [ECG] abnormalities, or cardiac imaging findings) lack symptoms of heart disease.</p><p>As noted above, some symptoms, such as dyspnea, are nonspecific and are evaluated in the context of concurrent symptoms, signs, and test findings to determine if they are more likely caused by a noncardiac condition (eg, pneumonia) or cardiac disease. (See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Targeted cardiac evaluation'</a>.)</p><p class="headingAnchor" id="H326792688"><span class="h2">Myocardial injury</span><span class="headingEndMark"> — </span>Myocardial injury as detected by troponin elevation is commonly identified in patients hospitalized with COVID-19, but the causes of myocardial injury have not been fully elucidated [<a href="#rid22">22</a>]. Cardiac troponin elevation does not distinguish among the causes of injury  (<a class="graphic graphic_table graphicRef54910" href="/d/graphic/54910.html" rel="external">table 1</a>). As discussed above, there are many putative causes of myocardial injury in patients with COVID-19, but the cause in individual patients is frequently not identified. Clinical conditions associated with myocardial injury include myocarditis, stress cardiomyopathy, and myocardial infarction (MI). (See <a class="local">'Possible causes'</a> above.)</p><p>The term "myocardial injury" encompasses all conditions causing cardiomyocyte death. Cardiac troponin elevation is the generally accepted marker for identifying myocardial injury [<a href="#rid23">23</a>]. Myocardial injury is commonly clinically identified by the presence of at least one cardiac troponin value above the 99<sup>th</sup> percentile upper reference limit (URL), in accordance with the definition of myocardial injury in the Fourth Universal Definition of Myocardial Infarction [<a href="#rid23">23</a>]. While high-sensitivity cardiac troponin levels are sensitive markers of myocardial injury, some patients with disease processes causing cardiomyocyte death may have troponin levels below the 99<sup>th</sup> percentile URL [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a> and  <a class="medical medical_review" href="/d/html/115187.html" rel="external">"Troponin testing: Analytical considerations"</a> and  <a class="medical medical_review" href="/d/html/1469.html" rel="external">"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome"</a> and  <a class="medical medical_review" href="/d/html/97.html" rel="external">"Use of creatine kinase to detect myocardial injury"</a> and <a class="local">'Troponin'</a> below.)</p><p class="headingAnchor" id="H2190103753"><span class="h3">Myocarditis</span><span class="headingEndMark"> — </span>Numerous COVID-19 case reports have described findings consistent with a diagnosis of "clinically suspected myocarditis" [<a href="#rid25">25-31</a>]. However, there have been few cases of histologically confirmed myocarditis [<a href="#rid32">32-34</a>], viral myocarditis caused directly by SARS-CoV-2 has not been definitively confirmed [<a href="#rid32">32,35,36</a>], and signs of myocardial injury consistent with myocarditis are no more frequent in patients with COVID-19 than they are in appropriate controls [<a href="#rid37">37,38</a>]. (See <a class="local">'Myocardial histology and viral genome analysis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective case-control study in which subjects underwent cardiovascular magnetic resonance (CMR) imaging within 28 days of hospitalization, patients hospitalized with COVID-19 who had an elevated troponin did not have a higher prevalence of nonischemic findings indicative of myocarditis compared with two groups of controls (13 versus 5 percent in patients hospitalized with COVID-19 but without troponin elevation and 14 percent in comorbidity-matched outpatients without COVID-19) [<a href="#rid37">37</a>]. However, in patients hospitalized with COVID-19 who had elevated troponin, there was a higher rate of CMR findings indicative of ischemic injury compared with the control groups; this finding had no apparent prognostic value in terms of mortality rates at 12 months.</p><p></p><p>A potential association between mRNA vaccines to prevent SARS-CoV-2 infection and myocarditis is discussed separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Myocarditis'</a>.)</p><p class="headingAnchor" id="H576251132"><span class="h3">Stress cardiomyopathy</span><span class="headingEndMark"> — </span>Stress (takotsubo) cardiomyopathy has been reported in patients with COVID-19 [<a href="#rid1">1,2,39-48</a>]. In addition, some case reports of clinically suspected myocarditis complicating COVID-19 have described marked recovery of left ventricular (LV) systolic function within days, suggestive of stress cardiomyopathy or fulminant myocarditis.</p><p>In a review of 12 cases of stress cardiomyopathy associated with COVID-19, the mean age was 70.8 and the majority of patients were female [<a href="#rid48">48</a>]. An elevated troponin level was identified in 11 of the cases. There was no significant coronary artery disease on invasive coronary angiography in two patients, coronary artery disease in arteries supplying a different territory in one case, negative computed tomography coronary angiography in five cases, and no coronary artery disease on autopsy in one case; the coronary arteries were not examined in three cases. Complications included HF, cardiogenic shock, cardiac tamponade, and hypertensive crisis. (See  <a class="medical medical_review" href="/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy"</a>.)</p><p>Of note, a study identified increased incidence of stress cardiomyopathy in patients without COVID-19 during the COVID-19 pandemic compared with prepandemic periods [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H511192822"><span class="h3">Myocardial infarction</span><span class="headingEndMark"> — </span>MI in patients with COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues"</a>.)</p><p class="headingAnchor" id="H3879490483"><span class="h2">Heart failure</span></p><p class="headingAnchor" id="H819008513"><span class="h3">General prevalence</span><span class="headingEndMark"> — </span>HF in patients with COVID-19 may be precipitated by acute illness in patients with preexisting known or undiagnosed heart disease (eg, coronary artery disease or hypertensive heart disease), acute hemodynamic stress (eg, acute cor pulmonale), or acute myocardial injury (eg, acute MI, stress cardiomyopathy, cytokine storm, and other possible etiologies described above) [<a href="#rid50">50-52</a>]. Cardiovascular risk factors and cardiovascular disease are highly prevalent in hospitalized patients with COVID-19. Patients with a known history of HF may suffer an acute decompensation due to the development of COVID-19 disease [<a href="#rid21">21,28</a>]. (See <a class="local">'Impact of preexisting cardiovascular disease'</a> above and  <a class="medical medical_review" href="/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues", section on 'Association between baseline CVD and COVID-19'</a>.)</p><p>A study of 6439 patients hospitalized with COVID-19 at a hospital in New York found that a history of HF was associated with adverse outcomes, including longer length of stay (eight versus six days), increased risk of mechanical ventilation (22.8 versus 11.9 percent; adjusted odds ratio [OR] 3.64, 95% CI 2.56-5.16), and mortality (40.0 versus 24.9 percent; adjusted OR 1.88, 95% CI 1.27-2.78) [<a href="#rid53">53</a>]. Outcomes among patients with different types of HF were similar, regardless of LV ejection fraction (LVEF).</p><p>Limited data are available on the incidence of HF in patients with COVID-19.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 6439 patients with COVID-19 admitted to hospitals in New York City between February 2020 and June 2020, 0.6 percent of patients were diagnosed with new HF [<a href="#rid54">54</a>]. Among the patients with a new diagnosis of HF, 22 percent had no risk factors for cardiovascular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 799 patients hospitalized with COVID-19 in Wuhan, HF was identified as a complication in 49 percent of patients who died and in 3 percent of patients who recovered, despite a less than 1 percent baseline prevalence of chronic HF in the combined groups [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 191 patients hospitalized in two other medical centers in Wuhan, HF was identified in 52 percent of patients who died and in 12 percent of patients who recovered [<a href="#rid56">56</a>]. These studies do not provide sufficient information to determine the incidence of new-onset HF with COVID-19, as there was not enough information provided regarding prior history of HF and risk factors for HF.</p><p></p><p>Although acute HF incidence was not documented in some series of hospitalized patients with COVID-19, elevated natriuretic peptides (such as B-type natriuretic peptide [BNP] and N-terminal pro-BNP [NT-proBNP]) are common, particularly in patients with evidence of cardiac injury, as described below. (See <a class="local">'Biomarkers'</a> below and <a class="local">'Natriuretic peptides'</a> below.)</p><p class="headingAnchor" id="H4072900703"><span class="h3">Right heart failure</span><span class="headingEndMark"> — </span>Acute cor pulmonale (right HF due to acute pulmonary hypertension) precipitated by acute pulmonary embolism or adult respiratory distress syndrome (ARDS) has been described in patients with COVID-19 [<a href="#rid5">5-10,57</a>]. Patients with COVID-19 are at risk for development of ARDS. Venous thromboembolism (including extensive deep vein thrombosis and pulmonary embolism) is common in acutely ill patients with COVID-19. (See  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a> and  <a class="medical medical_review" href="/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p class="headingAnchor" id="H233666396"><span class="h3">Cardiogenic shock</span><span class="headingEndMark"> — </span>Case reports have described patients with COVID-19 and acute onset of cardiogenic shock treated with inotrope and mechanical circulatory support and, in some cases, venoarterial extracorporeal membrane oxygenation (VA-ECMO) [<a href="#rid27">27,58</a>]. Rapid recovery within several days has been described in several reported cases with a time course suggestive of possible stress cardiomyopathy [<a href="#rid28">28,29,59-62</a>]. Although fulminant myocarditis was suspected in some cases of cardiogenic shock with recovery of ventricular function over days or weeks, this diagnosis has generally not been established, as endomyocardial biopsy was either not performed [<a href="#rid26">26,28,59,61,62</a>] or, when performed, did not show findings of myocarditis [<a href="#rid29">29,60</a>].</p><p class="headingAnchor" id="H544405150"><span class="h3">Multisystem inflammatory syndrome in adults (MIS-A)</span><span class="headingEndMark"> — </span>Multisystem inflammatory syndrome (MIS) was initially described in children (MIS-C) with recent COVID-19 infection as a Kawasaki-like illness associated with fever, gastrointestinal symptoms, shock, LV systolic dysfunction, and elevated inflammatory markers. (See  <a class="medical medical_review" href="/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p>Similar cases of MIS have been described in young to middle-aged adults (MIS-A) also presenting with fever, gastrointestinal symptoms, and shock with vasoplegia, LV systolic dysfunction, and elevated inflammatory markers [<a href="#rid63">63,64</a>]. Many of these patients had history of recent COVID-19 and had positive SARS-CoV-2 antibody tests, with fewer having positive SARS-CoV-2 reverse transcription polymerase chain reaction tests. This diagnosis should be considered in young adults presenting with shock and elevated inflammatory markers. This syndrome appears to be highly responsive to parenteral steroids. (See  <a class="medical medical_review" href="/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 as a risk factor for rheumatologic disease'</a>.)</p><p class="headingAnchor" id="H2709518090"><span class="h2">Cardiac arrhythmias</span><span class="headingEndMark"> — </span>The risk of cardiac arrhythmias and sudden cardiac arrest in patients with COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127551.html" rel="external">"COVID-19: Arrhythmias and conduction system disease"</a>.)</p><p class="headingAnchor" id="H2707351448"><span class="h1">CARDIAC TEST FINDINGS</span><span class="headingEndMark"> — </span>A variety of cardiac test abnormalities have been described in patients with COVID-19, as described in the following sections.</p><p class="headingAnchor" id="H987212793"><span class="h2">Biomarkers</span><span class="headingEndMark"> — </span>Cardiac troponin and natriuretic peptide (B-type natriuretic peptide [BNP] and N-terminal pro-BNP [NT-proBNP]) biomarkers are commonly elevated among hospitalized patients with COVID-19 and are associated with increased risk of mortality. In a study from Wuhan of 3219 patients (mean age 57 years) with COVID-19 hospitalized with biomarker data, elevated high-sensitivity cardiac troponin I (hs-cTnI) was detected in 6.5 percent, and an elevated NT-proBNP level was detected in 12.9 percent [<a href="#rid24">24</a>]. In a model including adjustment for age, sex, and comorbidities, the adjusted hazard ratio for 28-day mortality for hs-cTnI was 7.12 (95% CI 4.60-11.03) and for NT-proBNP was 5.11 (95% CI 3.50-7.47). These biomarkers had prognostic value at approximately half of the commonly used upper limit of normal thresholds.</p><p>A similar association between biomarker elevation and mortality risk was observed in a study from Milan of 397 hospitalized patients with COVID-19 [<a href="#rid65">65</a>]. At the time of hospital admission, 22.7 percent had elevated hs-cTnI and BNP levels, 14.9 percent had only an elevated BNP level, and 10.1 percent had only an elevated hs-cTnI. Overall mortality rate was 23.2 percent. The mortality rate was higher in patients with elevation of both biomarkers (55.6 percent), elevated BNP (33.9 percent), or hs-cTnI elevation (22.5 percent) compared with patients with no biomarker elevation (6.25 percent). In multivariate analysis, elevation of both hs-cTnI and BNP was an independent predictor of mortality (odds ratio [OR] 3.24, 95% CI 1.06-9.93).</p><p class="headingAnchor" id="H1967393526"><span class="h3">Troponin</span><span class="headingEndMark"> — </span>Cardiac troponin elevation is a marker of myocardial injury and is commonly identified in patients hospitalized with COVID-19, but the causes of troponin elevation have not been fully elucidated [<a href="#rid22">22</a>]. The frequency of myocardial injury (as reflected by elevation in cardiac troponin levels) is variable among hospitalized patients with COVID-19, with reported frequencies of 7 to 36 percent [<a href="#rid11">11,66-71</a>]. The frequency of troponin elevation appears to be lower among patients with mildly symptomatic COVID-19 [<a href="#rid72">72</a>]. Frequencies of troponin elevation in various COVID-19 series are difficult to compare due to use of differing troponin assays, 99<sup>th</sup> percentile upper reference limit (URL) thresholds, and sampling times [<a href="#rid73">73</a>]. Limited data are available on the frequency of troponin elevations in asymptomatic or only mildly symptomatic patients with SARS-CoV-2 infection. (See <a class="local">'Possible causes'</a> above and <a class="local">'Myocardial injury'</a> above.)</p><p>Studies have identified greater frequency and magnitude of troponin elevations in hospitalized patients with more severe disease and worse outcomes [<a href="#rid11">11,17,56,66,69,70,74,75</a>]. A systematic review and meta-analysis found that an elevated troponin level was among the clinical factors most strongly associated with an adverse composite outcome (including death, severe presentation, hospitalization in the intensive care unit, and/or mechanical ventilation; OR 10.58, 95% CI 5.00-22.40) [<a href="#rid17">17</a>]. Other clinical features associated with high risk of the composite outcomes were history of cardiovascular disease, acute kidney injury, increased procalcitonin, increased D-dimer, and thrombocytopenia. An elevated troponin level was also one of the clinical features associated with in-hospital death.</p><p>In a study from New York of 2736 hospitalized patients (mean age 66.4 years) with COVID-19, 36 percent of patients had elevated hs-cTnI levels [<a href="#rid71">71</a>]. Troponin elevation was more prevalent among patients with known cardiovascular disease or cardiovascular risk factors. The mortality rate during hospitalization was 18.5 percent. In adjusted analysis, even mildly elevated hs-cTnI (0.03 to 0.09 ng/mL) was associated with risk of death (adjusted hazard ratio [HR] 1.75, 95% CI 1.37-2.24), while greater elevations were associated with higher risk (troponin &gt;0.09 ng/mL; adjusted HR 3.03, 95% CI 2.42-3.80).</p><p>In a series of 416 patients with COVID-19 who were hospitalized at Renmin Hospital in Wuhan, 19.7 percent had hs-cTnI above the 99<sup>th</sup> percentile URL on admission [<a href="#rid11">11</a>]. Patients with this marker of myocardial injury were older and had more comorbidities (including chronic HF in 14.6 versus 1.5 percent), greater laboratory abnormalities (including higher levels of C-reactive protein, procalcitonin, and aspartate aminotransferase), more lung radiographic abnormalities, and more complications compared with those without myocardial injury. The mortality rate was also higher in those with myocardial injury (51.2 versus 4.5 percent). The risk of death starting from the time of symptom onset was more than four times higher in patients with evidence of myocardial injury on admission (HR 4.26, 95% CI 1.92-9.49).</p><p>In a study from Wuhan of 311 hospitalized patients with COVID-19 and available hs-cTnI levels, independent risk factors for death included hs-cTnI concentration (OR 1.92, 95% CI 1.41-2.59), comorbidity (OR 9.07, 95% CI 2.52-32.66), C-reactive protein concentration (OR 1.98, 95% CI 1.34-2.92), D-dimer concentration (OR 1.55, 95% CI 1.13-2.13), lymphocyte count (OR 0.52, 95% CI 0.29-0.95), and blood oxygen saturation (OR 0.85, 95% CI 0.77-0.94) [<a href="#rid75">75</a>].</p><p>In another study from Wuhan, elevation in hs-cTnI above the 99<sup>th</sup> percentile URL was identified on admission in 46 percent of nonsurvivors versus 1 percent of survivors [<a href="#rid56">56</a>]. In contrast, a study of 24 critically ill COVID-19 patients in Seattle with a 50 percent mortality rate found elevated troponin levels early after intensive care unit admission in only 2 of 13 (15 percent) tested patients, but troponin assays may have differed [<a href="#rid68">68</a>]. A study found considerably greater prevalence of preexisting cardiovascular disease and cardiac risk factors in patients with evidence of myocardial injury compared with those without elevated biomarkers [<a href="#rid11">11</a>]. Thus, it is not yet possible to determine whether myocardial injury is an independent risk marker in COVID-19 or if the risk associated with it is related to the burden of preexisting cardiovascular disease.</p><p>In patients with COVID-19, troponin elevation may be initially detected prior to, at the time of, or following hospital admission [<a href="#rid25">25-28,56,67,69,76</a>]. A variety of time courses for troponin elevation have been observed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – Patients hospitalized with COVID-19 commonly have mild troponin elevation (typically &lt;99<sup>th</sup> percentile URL), with modest rise or fall on subsequent days, typically remaining well below the 99<sup>th</sup> percentile URL [<a href="#rid67">67</a>]. This appears to be the most common pattern of troponin elevation in patients with COVID-19 and is often associated with no cardiac symptoms. This pattern has been described in patients with COVID-19 who survived after hospitalization [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate time-limited</strong> – Some patients have an early moderately elevated troponin level (which may approach or exceed the 99<sup>th</sup> percentile URL), which may fall on subsequent days. This pattern was seen in anecdotal reports of patients with clinically suspected myocarditis or stress cardiomyopathy [<a href="#rid25">25-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive</strong> – Some patients with moderate troponin elevation at hospital admission suffer clinical deterioration with respiratory failure accompanied by progressive troponin elevation, along with elevations in other biomarkers (eg, D-dimer, interleukin 6, ferritin, and lactate dehydrogenase) with accelerated rise after the second week of hospitalization [<a href="#rid56">56,69</a>]. This progression to cytokine storm has been described in nonsurvivors, with death occurring at a median of 18.5 days after symptom onset [<a href="#rid56">56</a>].</p><p></p><p>Other cardiac test abnormalities (such as ECG alterations and cardiac imaging findings) have been observed in patients with and without elevated troponin levels. The finding of a cardiac test abnormality without concurrent troponin elevation suggests a condition not associated with myocardial injury (including preexisting cardiac disease or a process not causing cardiomyocyte death) or a missed troponin level elevation due to limited troponin sampling or troponin elevation below 99<sup>th</sup> percentile URL thresholds [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'ECG'</a>.)</p><p class="headingAnchor" id="H2138439414"><span class="h3">Natriuretic peptides</span><span class="headingEndMark"> — </span>Natriuretic peptides (BNP and NT-proBNP) are commonly elevated in hospitalized patients with COVID-19, and natriuretic peptide elevation is associated with mortality risk, as described above. (See <a class="local">'Biomarkers'</a> above.).</p><p>Natriuretic peptide elevation is commonly associated with cardiac troponin elevation. In the above described series of 416 hospitalized patients with COVID-19, NT-proBNP levels were significantly higher in patients with elevated troponin levels than in patients without troponin elevation (1689 versus 139 pg/mL) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H748318670"><span class="h2">Electrocardiogram</span><span class="headingEndMark"> — </span>The various ECG findings observed in patients with COVID-19 likely reflect the combined effects of acute illness and chronic heart disease (since cardiovascular risk factors are highly prevalent in this population). The range of ECG findings was illustrated in a study of 756 patients (mean age 63 years) hospitalized with COVID-19 in New York [<a href="#rid77">77</a>]. The mortality rate was 11.9 percent during the follow-up period of two to seven weeks. Cardiovascular risk factors and conditions were common, including obesity (37 percent), diabetes mellitus (29 percent), hypertension (57 percent), coronary artery disease (CAD, 14 percent) and HF (7 percent). This study did not include data on troponin levels or comparison with prior ECGs.</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation or flutter was observed in 5.6 percent. Atrial premature beats (APBs) were observed in 7.7 percent and premature ventricular contractions in 3.4 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Right bundle branch block (RBBB) was identified in 7.8 percent, left bundle branch block in 1.5 percent, and nonspecific intraventricular conduction delay (IVCD) in 2.5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repolarization abnormalities included localized ST elevation in 0.7 percent, localized T-wave inversion in 10.5 percent, and nonspecific repolarization abnormalities in 29 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multivariable model including age, clinical characteristics, and ECG findings, the variables associated with risk of death were presence of CAD, an immunosuppressed state, hypoxemia, and the following ECG findings: APBs (OR 2.57, 95% CI 1.23-5.36), RBBB or IVCD (OR 2.61, 95% CI 1.32-5.18), localized T-wave inversion (OR 3.49, 95% CI 1.56-7.80), and nonspecific repolarization abnormality (OR 2.31, 95% CI 1.27-4.21).</p><p></p><p class="headingAnchor" id="H3291843790"><span class="h2">Cardiac imaging</span></p><p class="headingAnchor" id="H124747973"><span class="h3">Echocardiogram</span><span class="headingEndMark"> — </span>A variety of echocardiographic findings have been identified in patients with COVID-19 [<a href="#rid78">78-81</a>], as illustrated by a study of an unselected population of 100 patients hospitalized with COVID-19 [<a href="#rid81">81</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Transthoracic echocardiography (TTE) findings included right ventricular (RV) dilation and dysfunction (39 percent), LV diastolic dysfunction (16 percent), and LV systolic dysfunction (10 percent). Patients with an elevated troponin level or worse clinical condition had worse RV function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the 20 percent of patients with subsequent clinical deterioration, the most common echocardiographic findings were worsened RV function (12 patients) and worsened LV systolic and diastolic function (5 patients). Femoral deep vein thrombosis was identified in 5 of 12 patients with RV failure.</p><p></p><p>The spectrum of findings in patients with COVID-19 with a clinical indication for TTE was illustrated by an international survey including data on 1216 patients (mean age 62) from 69 countries [<a href="#rid78">78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common indications for TTE were suspected left-sided HF (40 percent), elevated cardiac biomarkers (26 percent), and right-sided HF (20 percent). Preexisting heart disease was noted in 26 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fifty-five percent of patients had an abnormal TTE, including LV abnormalities in 39 percent and RV abnormalities is 33 percent. A slightly lower prevalence of echocardiographic abnormalities (46 percent) was detected in the subgroup of patients with no known preexisting heart disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TTE LV findings were considered suggestive of diagnoses including acute MI (3 percent), myocarditis (3 percent), and stress cardiomyopathy (3 percent). Severe ventricular (left, right, or biventricular) dysfunction was observed in 14 percent. Cardiac tamponade was identified in 1 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TTE findings changed management in 33 percent of patients.</p><p></p><p>The prognostic importance of major TTE abnormalities was demonstrated by a study of 305 patients (mean age 63 years) who had undergone TTE during hospitalization for COVID-19 [<a href="#rid82">82</a>]. Troponin elevation was observed in 62.3 percent of these patients. Patients with troponin elevation had more ECG abnormalities and higher prevalence of major TTE abnormalities (including LV wall motion abnormalities, global LV dysfunction, LV diastolic dysfunction grade II or III, RV dysfunction, and pericardial effusions) than patients without troponin elevation. Rates of in-hospital mortality were 5.2 percent in patients without myocardial injury, 18.6 in those with myocardial injury without TTE abnormalities, and 31.7 percent in patients with myocardial injury and TTE abnormalities. Following multivariable adjustment, myocardial injury with TTE abnormalities was associated with higher risk of death, but myocardial injury without TTE abnormalities was not.</p><p class="headingAnchor" id="H3896449799"><span class="h3">Cardiovascular magnetic resonance</span><span class="headingEndMark"> — </span>Cardiovascular magnetic resonance (CMR) abnormalities have been identified in patients with COVID-19 as well as in patients who have recently recovered from COVID-19, though most reported abnormalities have been nonspecific. CMR findings identified in some of these patients include elevations in native T1 (a nonspecific finding seen with acute myocardial injury, fibrosis, or infiltration), T2 (a marker of edema), and, less commonly, late gadolinium enhancement (a marker of acute myocardial injury, fibrosis, or infarction). Since limited endomyocardial biopsy data and no follow-up data have been reported, the clinical significance of these findings is uncertain. Moreover, since no patients had a CMR examination before COVID-19, it remains undetermined whether the abnormal findings might have already been present and therefore be unrelated to COVID-19. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Myocardial disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>In an unselected cohort</strong> – A CMR study included 100 patients (mean age 49 years) who had recovered from COVID-19, including 18 with asymptomatic SARS-CoV-2 infection, 49 with mild to moderate symptoms, and 33 with severe symptoms requiring hospitalization [<a href="#rid83">83</a>]. Preexisting cardiovascular conditions such as hypertension, diabetes mellitus, and known coronary artery disease were equally common among patients who remained at home and those who were hospitalized. Patients referred for CMR for cardiac symptoms were excluded. Comparisons were made with healthy controls as well as with risk factor-matched controls.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the 33 hospitalized patients, 15 patients had a significantly elevated hs-cTnI during hospitalization. Among all the patients, 5 percent has significant hs-cTnI elevation at the time of CMR. CMR was performed two to three months after the initial positive COVID-19 test.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal CMR findings were frequent among those who had recovered from COVID-19, including elevated myocardial native T1 (73 percent), elevated myocardial native T2 (60 percent), myocardial late gadolinium enhancement (LGE; 32 percent), and pericardial LGE (22 percent). Baseline CMR data were not available.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In healthy controls, T1 and T2 elevations were rare and LGE was not seen.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In risk-factor matched controls, CMR abnormalities were identified, although at lower frequencies than in the COVID-19 group: elevated native T1 (40 percent), elevated native T2 (9 percent), myocardial LGE (17 percent), and pericardial LGE (15 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endomyocardial biopsy in three patients with elevated hs-cTnI, elevated native T1 and T2, LGE, and LVEF &lt;50 percent revealed lymphocytic infiltration; necrosis was not described and no viral genome was detected.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The LV was mildly dilated and LVEF and RVEF were mildly depressed in patients recovered from COVID-19 compared with healthy controls and risk-factor matched controls (for LVEF 56 versus 60 and 61 percent, respectively; for RVEF 56 versus 60 and 59 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In athletes</strong> – CMR findings have also been reported among athletes who have recovered from COVID-19 [<a href="#rid84">84-87</a>]. The clinical significance of these findings is uncertain since CMR findings are nonspecific and endomyocardial biopsy data were not reported. Studies have identified CMR findings including LGE in a minority of healthy adult athletes with no prior COVID-19 infection [<a href="#rid88">88-91</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Collegiate athletes</strong> – After small studies identified CMR abnormalities in collegiate athletes recovering from COVID-19 [<a href="#rid84">84,91</a>], a larger study found that CMR findings consistent with clinically suspected myocarditis were rare [<a href="#rid86">86</a>]. In a study of 145 university student athletes (mean age 20 years; 74 percent male), CMR examination was performed at a median of 15 days after the positive COVID-19 tests [<a href="#rid86">86</a>]. Most patients experienced mild, moderate, or no symptoms during the acute COVID-19 infection. Two patients (1.4 percent) had findings consistent with updated Lake Louise criteria for clinically suspected myocarditis (see  <a class="medical medical_review" href="/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Updated Lake Louise criteria'</a>). One of these patients had patchy midmyocardial and subepicardial LGE with associated elevated T2-weighted signal, transient troponin I elevation, and pericardial enhancement. CMR examination of the second patient revealed a 1 cm focus of mild epicardial LGE at the inferior basal LV wall with corresponding elevated T2-weighted signal; an additional small nonspecific LGE focus was identified at the inferior RV insertion. No endomyocardial biopsy data were available. 40 patients (27.6 percent) had small nonspecific foci of LGE.</p><p></p><p class="bulletIndent2">In an earlier study of 26 competitive collegiate athletes (mean age 19.5 years), CMR examination was performed 11 to 53 days after diagnosis of COVID-19 [<a href="#rid84">84</a>]. Twelve athletes had experienced mild COVID-19 symptoms and 14 were asymptomatic. None of the athletes had elevated serum troponin I levels or diagnostic ST/T-wave changes on ECG. Ventricular volumes and function were normal on echocardiogram and CMR imaging. Four athletes (15 percent) had CMR findings consistent with updated Lake Louise criteria for clinically suspected myocarditis. Eight athletes (30 percent) had nonspecific LGE.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Professional athletes</strong> – A protocol for return-to-play cardiac testing in professional athletes also identified a low rate of CMR findings consistent with clinically suspected myocarditis [<a href="#rid87">87</a>]. Return-to-play testing was performed between May and October 2020 in 789 professional athletes (mean age 35, 98.5 percent male) [<a href="#rid87">87</a>]. Return-to-play testing was performed in patients with prior symptomatic COVID-19 (58 percent) as well as in patients with asymptomatic or mildly symptomatic infection (42 percent) and included a troponin level, a 12-lead ECG, and a resting transthoracic echocardiogram. Among the 30 athletes (3.8 percent) with one or more abnormal screening test results, 27 underwent CMR. CMR findings consistent with clinically suspected myocarditis were identified in 3 athletes (0.4 percent of the cohort) and with pericarditis in 2 athletes (0.3 percent).</p><p></p><p class="headingAnchor" id="H589742952"><span class="h2">Myocardial histology and viral genome analysis</span><span class="headingEndMark"> — </span>Myocarditis is commonly suspected in patients with COVID-19 and elevated cardiac troponin levels. However, there have been few reported cases of histologically confirmed myocarditis [<a href="#rid32">32-34</a>], and viral myocarditis directly caused by SARS-CoV-2 has not been definitively confirmed by histologic and viral genome analysis [<a href="#rid32">32</a>]. Immune-mediated myocarditis has been hypothesized but not confirmed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral myocarditis</strong> – Proof that SARS-CoV-2 is a cause of viral myocarditis requires identification of histologic findings of active myocarditis (ie, inflammatory infiltrate [lymphocytic, eosinophilic, neutrophilic, giant cell, granulomatous, or mixed] plus myocyte necrosis not typical of ischemic injury [<a href="#rid92">92</a>]), identification of the SARS-CoV-2 genome or viral particles in cardiomyocytes, and exclusion of known cardiotropic viruses [<a href="#rid12">12</a>]. Cardiotropic viruses that are known to be associated with myocarditis (eg, enterovirus, which is associated with diarrhea, and parvovirus B19, which is associated with a pseudoinfarct presentation) were not searched for in most of the reported cases and might be involved.</p><p></p><p class="bulletIndent1">Case series and reports that have included endomyocardial biopsy results illustrate that identification of SARS-CoV-2 in specimens from the upper or lower respiratory tract is not sufficient to prove that concomitant myocardial injury was caused by SARS-CoV-2 myocarditis [<a href="#rid3">3,25-27,83</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a few patients with COVID-19, myocarditis has been histologically confirmed but viral genome was not identified in the myocardium [<a href="#rid34">34,93,94</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a series of 104 patients undergoing endomyocardial biopsy for suspected myocarditis or unexplained HF during the COVID-19 pandemic, low loads of SARS-CoV-2 genome were detected in biopsy tissue in five cases [<a href="#rid32">32</a>]. Among these five cases, Dallas criteria for myocarditis were met in one patient and another patient had evidence of borderline myocarditis. However, blood samples were not examined to determine whether the detected SARS-CoV-2 genome might have resulted from circulating blood.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A case report described a patient with COVID-19 who developed cardiogenic shock; light and electron microscopy of endomyocardial biopsy specimens revealed low-grade interstitial and endocardial inflammation, with viral particles identified in cytopathic macrophages but not in cardiomyocytes, which showed nonspecific features (eg, focal myofibrillar lysis and lipid droplets) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">In autopsy series, the above described requirements for identification of SARS-CoV-2 viral myocarditis have not been met [<a href="#rid36">36,95-102</a>], as illustrated by the following examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An international multicenter study of cardiac tissue from the autopsies of 21 patients with COVID-19 found increased interstitial macrophage infiltration in 18 cases (86 percent) and lymphocytic infiltration in 3 cases (14 percent) [<a href="#rid103">103</a>]. Acute myocyte injury in the RV was identified in four cases. Troponin levels were nominally but not significantly higher among patients with lymphocytic infiltration. Electron microscopy was performed on only three cases without myocarditis and was negative for virions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report from Hamburg of autopsies performed in 12 patients with COVID-19, lymphocytic infiltrates without myocyte necrosis were identified in the RV myocardium in one patient who died of pulmonary embolism and pneumonia [<a href="#rid6">6</a>]. The SARS-CoV-2 genome was found in the myocardium in this case and in other patients in this series without lymphocytic infiltrates in the myocardium [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another study from Hamburg described cardiac tissue findings in 39 autopsy cases with confirmed COVID-19 [<a href="#rid102">102</a>]. Viral load above 1000 copies per mcg RNA was identified in 16 of 39 patients (41 percent). A cytokine response panel of six proinflammatory genes was increased in those 16 patients compared with 15 patients without SARS-CoV-2 in cardiac tissue. However, there were no significant inflammatory cell infiltrates associated with SARS-CoV-2 in the heart.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report from Brussels of postmortem findings in 17 patients with COVID-19, all except two patients had one or more comorbidity (such as hypertension, diabetes mellitus, cerebrovascular disease, coronary artery disease, and cancer) [<a href="#rid96">96</a>]. There was no evidence of myocarditis in any of the patients. Two patients had evidence of acute MI and 15 patients had signs of chronic ischemic heart disease.</p><p></p><p class="bulletIndent1">Further investigation, including histologic examination of cardiac tissue in COVID-19 patients, is required to characterize the relationship between COVID-19 and myocardial injury. Since biopsy-proven myocarditis may occur in the absence of troponin release, autopsy studies of COVID-19 victims, regardless of troponin levels, are helpful in clarifying whether SARS-CoV-2 is a new cause of viral myocarditis [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune myocarditis</strong> –<strong> </strong>The possibility of COVID-19-associated myocarditis (ie, myocarditis caused by immune activation and not direct infection) has been suggested but not established. Data to support this hypothesis are limited by the nonsystematic approaches to diagnosis of myocarditis (eg, lack of endomyocardial biopsy with virological analysis, failure to exclude other causes of myocardial inflammation or injury) [<a href="#rid12">12,35</a>]. Immune-mediated myocarditis requires biopsy proven evidence of a characteristic pattern of inflammation (eg, lymphocytic, eosinophilic, giant cells), cardiomyocyte necrosis not typical of infarction, and no evidence of infection as assessed by molecular techniques [<a href="#rid12">12,35,104</a>]. The presence of "inflammation" in the heart on noninvasive imaging and/or biochemical evidence of myocardial injury, with or without cardiac symptoms, is not sufficient to establish the diagnosis of immune-mediated myocarditis. For example, in a study of 112 cases of COVID-related "myocarditis," only 17 patients had a biopsy [<a href="#rid94">94</a>].</p><p></p><p class="headingAnchor" id="H1737515004"><span class="h1">LONG-TERM CARDIOVASCULAR EFFECTS</span><span class="headingEndMark"> — </span>Among patients who had COVID-19, the risk of cardiovascular (CV) disease may be increased due to the myocardial stress or hypercoagulable state associated with COVID-19 (see <a class="local">'Myocardial injury'</a> above). While no direct causal mechanism has been established between COVID-19 and CV disease, limited data suggest that patients who had COVID-19 may have a higher risk of CV disease when compared with patients who did not have COVID-19.</p><p>In a study that recorded the one-year incidence of CV disease among almost 5.8 million United States veterans, patients who had COVID-19 had an increased risk of death or major adverse CV events (eg, stroke, MI, arrhythmias, HF) when compared with a group of patients who did not have COVID-19 (23 excess CV events per 1000 patients with COVID-19; adjusted hazard ratio 1.55, 95% CI 1.5-1.6) [<a href="#rid105">105</a>]. In addition, patients hospitalized with more severe COVID-19 (ie, hospitalized for COVID-19) were more likely to develop CV disease when compared with patients with less severe COVID-19.</p><p class="headingAnchor" id="H2259781417"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H2095745399"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3891436593"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Adults with coronavirus disease 2019 (COVID-19) commonly have manifestations of heart disease including signs of myocardial injury, but the causes of these findings have not been established. Putative causes of myocardial injury in patients with COVID-19 include myocarditis, hypoxic injury, stress (takotsubo) cardiomyopathy, ischemic injury caused by cardiac microvascular damage or epicardial coronary artery disease (with plaque rupture or demand ischemia), right heart strain (cor pulmonale), and systemic inflammatory response syndrome (cytokine storm). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults with COVID-19 present with a broad spectrum of clinical cardiac presentations: some patients manifest no clinical evidence of heart disease, some have no symptoms of heart disease but have cardiac test abnormalities (such as serum cardiac troponin elevation, asymptomatic cardiac arrhythmias, or abnormalities on cardiac imaging), and some have symptomatic heart disease. Cardiac complications include myocardial injury, heart failure (HF), cardiogenic shock, multisystem inflammatory syndrome in adults, and cardiac arrhythmias including sudden cardiac arrest. (See <a class="local">'Acute clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial injury (as reflected in elevated cardiac troponin levels) is common among patients hospitalized with COVID-19, but the cause in individual patients is frequently not identified. The presence and magnitude of troponin elevation is associated with more severe disease and worse outcomes. Clinical conditions associated with myocardial injury include myocarditis, stress cardiomyopathy, and myocardial infarction. (See <a class="local">'Troponin'</a> above and <a class="local">'Myocardial injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HF in patients with COVID-19 may be precipitated by acute illness in patients with preexisting known or undiagnosed heart disease (eg, coronary artery disease or hypertensive heart disease), acute hemodynamic stress (eg, acute cor pulmonale), or incident acute myocardial injury. (See <a class="local">'Heart failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac troponin and natriuretic peptide (B-type natriuretic peptide [BNP] and N-terminal pro-BNP) biomarkers are commonly elevated among hospitalized patients with COVID-19 and are associated with increased risk of mortality. (See <a class="local">'Biomarkers'</a> above and <a class="local">'Troponin'</a> above and <a class="local">'Natriuretic peptides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography findings prevalent in patients with COVID-19 include right ventricular dilation and dysfunction and left ventricular diastolic and systolic dysfunction. (See <a class="local">'Echocardiogram'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular magnetic resonance abnormalities have been identified in patients who have recently recovered from COVID-19. Since limited endomyocardial biopsy data and no follow-up data have been reported, the clinical significance of these findings is uncertain. Moreover, since no patients had a CMR examination before COVID-19, it remains undetermined whether the abnormal findings might have already been present and therefore be unrelated to COVID-19. (See <a class="local">'Cardiovascular magnetic resonance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis is commonly suspected in patients with COVID-19 and elevated cardiac troponin levels. However, there have been few reported cases of histologically confirmed myocarditis, and viral myocarditis caused by SARS-CoV-2 has not been definitively confirmed by myocardial histologic and viral genome analysis. (See <a class="local">'Myocardial histology and viral genome analysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients who had COVID-19, the risk of cardiovascular (CV) disease may be increased. (See <a class="local">'Long-term cardiovascular effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Giustino G, Croft LB, Oates CP, et al. Takotsubo Cardiomyopathy in COVID-19. J Am Coll Cardiol 2020; 76:628.</a></li><li><a class="nounderline abstract_t">Tsao CW, Strom JB, Chang JD, Manning WJ. COVID-19-Associated Stress (Takotsubo) Cardiomyopathy. Circ Cardiovasc Imaging 2020; 13:e011222.</a></li><li><a class="nounderline abstract_t">Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann Intern Med 2020; 173:1025.</a></li><li><a class="nounderline abstract_t">Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417.</a></li><li><a class="nounderline abstract_t">Creel-Bulos C, Hockstein M, Amin N, et al. Acute Cor Pulmonale in Critically Ill Patients with Covid-19. N Engl J Med 2020; 382:e70.</a></li><li><a class="nounderline abstract_t">Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173:268.</a></li><li><a class="nounderline abstract_t">Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020; 41:1858.</a></li><li><a class="nounderline abstract_t">Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142:184.</a></li><li><a class="nounderline abstract_t">Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145.</a></li><li><a class="nounderline abstract_t">Huette P, Beyls C, Guilbart M, et al. Acute Cor Pulmonale in COVID-19-Related ARDS: Improvement With Almitrine Infusion. JACC Case Rep 2020; 2:1311.</a></li><li><a class="nounderline abstract_t">Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5:802.</a></li><li><a class="nounderline abstract_t">Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636.</a></li><li><a class="nounderline abstract_t">Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17:259.</a></li><li><a class="nounderline abstract_t">Tersalvi G, Vicenzi M, Calabretta D, et al. Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J Card Fail 2020; 26:470.</a></li><li><a class="nounderline abstract_t">Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41:3038.</a></li><li><a class="nounderline abstract_t">Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res 2020; 126:1443.</a></li><li><a class="nounderline abstract_t">Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest 2020; 50:e13362.</a></li><li><a class="nounderline abstract_t">Chatterjee NA, Cheng RK. Cardiovascular disease and COVID-19: implications for prevention, surveillance and treatment. Heart 2020; 106:1119.</a></li><li><a class="nounderline abstract_t">Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020; 133:1025.</a></li><li><a class="nounderline abstract_t">Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507.</a></li><li><a class="nounderline abstract_t">Dong N, Cai J, Zhou Y, et al. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail 2020; 8:515.</a></li><li><a class="nounderline abstract_t">Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2020; 76:1244.</a></li><li><a class="nounderline abstract_t">Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72:2231.</a></li><li><a class="nounderline abstract_t">Qin JJ, Cheng X, Zhou F, et al. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. Hypertension 2020; 76:1104.</a></li><li><a class="nounderline abstract_t">Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5:819.</a></li><li><a class="nounderline abstract_t">Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 2020; 48:773.</a></li><li><a class="nounderline abstract_t">Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J 2021; 42:206.</a></li><li><a class="nounderline abstract_t">Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation 2020; 141:1930.</a></li><li><a class="nounderline abstract_t">Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020; 22:911.</a></li><li><a class="nounderline abstract_t">Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J 2020; 41:1859.</a></li><li><a class="nounderline abstract_t">Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol 2021; 6:1078.</a></li><li><a class="nounderline abstract_t">Escher F, Pietsch H, Aleshcheva G, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail 2020; 7:2440.</a></li><li><a class="nounderline abstract_t">Salah HM, Mehta JL. Takotsubo cardiomyopathy and COVID-19 infection. Eur Heart J Cardiovasc Imaging 2020; 21:1299.</a></li><li><a class="nounderline abstract_t">Nicol M, Cacoub L, Baudet M, et al. Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. ESC Heart Fail 2020; 7:4371.</a></li><li><a class="nounderline abstract_t">Caforio ALP, Baritussio A, Basso C, Marcolongo R. Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection. Annu Rev Med 2022; 73:149.</a></li><li><a class="nounderline abstract_t">Kawakami R, Sakamoto A, Kawai K, et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol 2021; 77:314.</a></li><li><a class="nounderline abstract_t">Artico J, Shiwani H, Moon JC, et al. Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study. Circulation 2023; 147:364.</a></li><li><a class="nounderline abstract_t">Stuber M, Baggish AL. Acute Myocardial Injury in the COVID-HEART Study: Emphasizing Scars While Reassuring Scares. Circulation 2023; 147:375.</a></li><li><a class="nounderline abstract_t">Palmieri V, Di Pietro L, Perini G, et al. Graphene Oxide Nano-Concentrators Selectively Modulate RNA Trapping According to Metal Cations in Solution. Front Bioeng Biotechnol 2020; 8:421.</a></li><li><a class="nounderline abstract_t">Sang CJ 3rd, Heindl B, Von Mering G, et al. Stress-Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Coinfection. JACC Case Rep 2020; 2:1356.</a></li><li><a class="nounderline abstract_t">Bapat A, Maan A, Heist EK. Stress-Induced Cardiomyopathy Secondary to COVID-19. Case Rep Cardiol 2020; 2020:8842150.</a></li><li><a class="nounderline abstract_t">Minhas AS, Scheel P, Garibaldi B, et al. Takotsubo Syndrome in the Setting of COVID-19. JACC Case Rep 2020; 2:1321.</a></li><li><a class="nounderline abstract_t">Roca E, Lombardi C, Campana M, et al. Takotsubo Syndrome Associated with COVID-19. Eur J Case Rep Intern Med 2020; 7:001665.</a></li><li><a class="nounderline abstract_t">Park JH, Moon JY, Sohn KM, Kim YS. Two Fatal Cases of Stress-induced Cardiomyopathy in COVID-19 Patients. J Cardiovasc Imaging 2020; 28:300.</a></li><li><a class="nounderline abstract_t">Nguyen D, Nguyen T, De Bels D, Castro Rodriguez J. A case of Takotsubo cardiomyopathy with COVID 19. Eur Heart J Cardiovasc Imaging 2020; 21:1052.</a></li><li><a class="nounderline abstract_t">Meyer P, Degrauwe S, Van Delden C, et al. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J 2020; 41:1860.</a></li><li><a class="nounderline abstract_t">Faqihi F, Alharthy A, Alshaya R, et al. Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. BMC Cardiovasc Disord 2020; 20:389.</a></li><li><a class="nounderline abstract_t">Singh S, Desai R, Gandhi Z, et al. Takotsubo Syndrome in Patients with COVID-19: a Systematic Review of Published Cases. SN Compr Clin Med 2020; 2:2102.</a></li><li><a class="nounderline abstract_t">Jabri A, Kalra A, Kumar A, et al. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open 2020; 3:e2014780.</a></li><li><a class="nounderline abstract_t">Bader F, Manla Y, Atallah B, Starling RC. Heart failure and COVID-19. Heart Fail Rev 2021; 26:1.</a></li><li><a class="nounderline abstract_t">Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail 2020; 22:957.</a></li><li><a class="nounderline abstract_t">DeFilippis EM, Reza N, Donald E, et al. Considerations for Heart Failure Care During the COVID-19 Pandemic. JACC Heart Fail 2020; 8:681.</a></li><li><a class="nounderline abstract_t">Alvarez-Garcia J, Lee S, Gupta A, et al. Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. J Am Coll Cardiol 2020; 76:2334.</a></li><li><a class="nounderline abstract_t">Alvarez-Garcia J, Jaladanki S, Rivas-Lasarte M, et al. New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19. J Am Coll Cardiol 2021; 77:2260.</a></li><li><a class="nounderline abstract_t">Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.</a></li><li><a class="nounderline abstract_t">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.</a></li><li><a class="nounderline abstract_t">Ullah W, Saeed R, Sarwar U, et al. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. JACC Case Rep 2020; 2:1379.</a></li><li><a class="nounderline abstract_t">Zeng JH, Liu Y, Yuan J, et al. First case of COVID-19 infection with fulminant myocarditis complication: Case report and insights. Preprints 2020; 2020030180.</a></li><li><a class="nounderline abstract_t">Irabien-Ortiz Á, Carreras-Mora J, Sionis A, et al. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol (Engl Ed) 2020; 73:503.</a></li><li><a class="nounderline abstract_t">Salamanca J, Díez-Villanueva P, Martínez P, et al. COVID-19 "Fulminant Myocarditis" Successfully Treated With Temporary Mechanical Circulatory Support. JACC Cardiovasc Imaging 2020; 13:2457.</a></li><li><a class="nounderline abstract_t">Bernal-Torres W, Herrera-Escandón Á, Hurtado-Rivera M, Plata-Mosquera CA. COVID-19 fulminant myocarditis: a case report. Eur Heart J Case Rep 2020; 4:1.</a></li><li><a class="nounderline abstract_t">Richard I, Robinson B, Dawson A, et al. An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection. Cureus 2020; 12:e9179.</a></li><li><a class="nounderline abstract_t">Chau VQ, Giustino G, Mahmood K, et al. Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19. Circ Heart Fail 2020; 13:e007485.</a></li><li><a class="nounderline abstract_t">Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1450.</a></li><li><a class="nounderline abstract_t">Stefanini GG, Chiarito M, Ferrante G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart 2020; 106:1512.</a></li><li><a class="nounderline abstract_t">Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020; 63:390.</a></li><li><a class="nounderline abstract_t">Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation 2020; 141:1648.</a></li><li><a class="nounderline abstract_t">Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020; 382:2012.</a></li><li><a class="nounderline abstract_t">Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5:811.</a></li><li><a class="nounderline abstract_t">Wei JF, Huang FY, Xiong TY, et al. Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. Heart 2020; 106:1154.</a></li><li><a class="nounderline abstract_t">Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol 2020; 76:533.</a></li><li><a class="nounderline abstract_t">Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis 2020; 95:304.</a></li><li><a class="nounderline abstract_t">Sandoval Y, Bielinski SJ, Daniels LB, et al. Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium. J Am Coll Cardiol 2020; 76:357.</a></li><li><a class="nounderline abstract_t">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.</a></li><li><a class="nounderline abstract_t">Nie SF, Yu M, Xie T, et al. Cardiac Troponin I Is an Independent Predictor for Mortality in Hospitalized Patients With COVID-19. Circulation 2020; 142:608.</a></li><li><a class="nounderline abstract_t">Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 2020; 311:116.</a></li><li><a class="nounderline abstract_t">McCullough SA, Goyal P, Krishnan U, et al. Electrocardiographic Findings in Coronavirus Disease-19: Insights on Mortality and Underlying Myocardial Processes. J Card Fail 2020; 26:626.</a></li><li><a class="nounderline abstract_t">Dweck MR, Bularga A, Hahn RT, et al. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imaging 2020; 21:949.</a></li><li><a class="nounderline abstract_t">Zhang L, Wang B, Zhou J, et al. Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography. J Am Soc Echocardiogr 2020; 33:676.</a></li><li><a class="nounderline abstract_t">Teran F, Burns KM, Narasimhan M, et al. Critical Care Transesophageal Echocardiography in Patients during the COVID-19 Pandemic. J Am Soc Echocardiogr 2020; 33:1040.</a></li><li><a class="nounderline abstract_t">Szekely Y, Lichter Y, Taieb P, et al. Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study. Circulation 2020; 142:342.</a></li><li><a class="nounderline abstract_t">Giustino G, Croft LB, Stefanini GG, et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol 2020; 76:2043.</a></li><li><a class="nounderline abstract_t">Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1265.</a></li><li><a class="nounderline abstract_t">Rajpal S, Tong MS, Borchers J, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA Cardiol 2021; 6:116.</a></li><li><a class="nounderline abstract_t">Clark DE, Parikh A, Dendy JM, et al. COVID-19 Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR). medRxiv 2020.</a></li><li><a class="nounderline abstract_t">Starekova J, Bluemke DA, Bradham WS, et al. Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging. JAMA Cardiol 2021; 6:945.</a></li><li><a class="nounderline abstract_t">Martinez MW, Tucker AM, Bloom OJ, et al. Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening. JAMA Cardiol 2021; 6:745.</a></li><li><a class="nounderline abstract_t">Małek ŁA, Barczuk-Falęcka M, Werys K, et al. Cardiovascular magnetic resonance with parametric mapping in long-term ultra-marathon runners. Eur J Radiol 2019; 117:89.</a></li><li><a class="nounderline abstract_t">La Gerche A, Burns AT, Mooney DJ, et al. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J 2012; 33:998.</a></li><li><a class="nounderline abstract_t">Tahir E, Starekova J, Muellerleile K, et al. Impact of Myocardial Fibrosis on Left Ventricular Function Evaluated by Feature-Tracking Myocardial Strain Cardiac Magnetic Resonance in Competitive Male Triathletes With Normal Ejection Fraction. Circ J 2019; 83:1553.</a></li><li><a class="nounderline abstract_t">Clark DE, Parikh A, Dendy JM, et al. COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR). Circulation 2021; 143:609.</a></li><li><a class="nounderline abstract_t">Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1:3.</a></li><li><a class="nounderline abstract_t">Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 2020; 41:1861.</a></li><li><a class="nounderline abstract_t">Ammirati E, Lupi L, Palazzini M, et al. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. Circulation 2022; 145:1123.</a></li><li><a class="nounderline abstract_t">Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med 2020; 383:590.</a></li><li><a class="nounderline abstract_t">Remmelink M, De Mendonça R, D'Haene N, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care 2020; 24:495.</a></li><li><a class="nounderline abstract_t">Yao XH, Li TY, He ZC, et al. [A pathological report of three COVID-19 cases by minimal invasive autopsies]. Zhonghua Bing Li Xue Za Zhi 2020; 49:411.</a></li><li><a class="nounderline abstract_t">Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8:420.</a></li><li><a class="nounderline abstract_t">Barton LM, Duval EJ, Stroberg E, et al. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol 2020; 153:725.</a></li><li class="breakAll">https://www.medrxiv.org/content/10.1101/2020.04.06.20050575v1.full.pdf (Accessed on April 23, 2020).</li><li><a class="nounderline abstract_t">Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020; 33:1007.</a></li><li><a class="nounderline abstract_t">Lindner D, Fitzek A, Bräuninger H, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol 2020; 5:1281.</a></li><li><a class="nounderline abstract_t">Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 2020; 41:3827.</a></li><li><a class="nounderline abstract_t">Baritussio A, Schiavo A, Basso C, et al. Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. Eur J Heart Fail 2022; 24:1033.</a></li><li><a class="nounderline abstract_t">Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28:583.</a></li></ol></div><div id="topicVersionRevision">Topic 129342 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32517962" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Takotsubo Cardiomyopathy in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673494" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : COVID-19-Associated Stress (Takotsubo) Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726150" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32325026" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Endothelial cell infection and endotheliitis in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374956" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute Cor Pulmonale in Critically Ill Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374815" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227120" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute pulmonary embolism and COVID-19 pneumonia: a random association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330083" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291094" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of thrombotic complications in critically ill ICU patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835274" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute Cor Pulmonale in COVID-19-Related ARDS: Improvement With Almitrine Infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32211816" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824828" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139904" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : COVID-19 and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32315733" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32882706" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : COVID-19 is, in the end, an endothelial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32252591" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : COVID-19 and the Heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726868" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32451360" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiovascular disease and COVID-19: implications for prevention, surveillance and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044814" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007143" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32265149" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652195" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153967" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fourth Universal Definition of Myocardial Infarction (2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673499" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219357" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32277408" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : First case of COVID-19 complicated with fulminant myocarditis: a case report and insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32176300" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243205" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Variety of Cardiovascular Presentations of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32275347" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Myocardial localization of coronavirus in COVID-19 cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282027" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : COVID-19-related myocarditis in a 21-year-old female patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34042947" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32529795" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949135" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Takotsubo cardiomyopathy and COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33107217" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506211" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33478655" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36705028" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36716254" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Acute Myocardial Injury in the COVID-HEART Study: Emphasizing Scars While Reassuring Scares.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32523936" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Graphene Oxide Nano-Concentrators Selectively Modulate RNA Trapping According to Metal Cations in Solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835279" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Stress-Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Coinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32934848" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Stress-Induced Cardiomyopathy Secondary to COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32363351" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Takotsubo Syndrome in the Setting of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32399453" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Takotsubo Syndrome Associated with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33086446" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Two Fatal Cases of Stress-induced Cardiomyopathy in COVID-19 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32395765" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A case of Takotsubo cardiomyopathy with COVID 19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32285915" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Typical takotsubo syndrome triggered by SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32842957" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33043251" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Takotsubo Syndrome in Patients with COVID-19: a Systematic Review of Published Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32644140" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32720082" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Heart failure and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32412156" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32493638" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Considerations for Heart Failure Care During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33129663" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33926664" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : New Heart Failure Diagnoses Among Patients Hospitalized for COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217556" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171076" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32313884" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : First case of COVID-19 infection with fulminant myocarditis complication: Case report and insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345547" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fulminant myocarditis due to COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32713771" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : COVID-19 "Fulminant Myocarditis" Successfully Treated With Temporary Mechanical Circulatory Support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33089053" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : COVID-19 fulminant myocarditis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32802614" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844662" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031361" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32817312" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32169400" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32200663" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : COVID-19 and Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227758" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219356" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32354798" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32517963" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32344011" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mild versus severe COVID-19: Laboratory markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703505" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Atherosclerotic Cardiovascular Disease Risk Stratification Based on Measurements of Troponin and Coronary Artery Calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031570" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32539541" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cardiac Troponin I Is an Independent Predictor for Mortality in Hospitalized Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291207" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32544622" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Electrocardiographic Findings in Coronavirus Disease-19: Insights on Mortality and Underlying Myocardial Processes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556199" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Global evaluation of echocardiography in patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32503706" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32600742" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Critical Care Transesophageal Echocardiography in Patients during the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469253" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33121710" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Characterization of Myocardial Injury in Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730619" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32915194" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32908996" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : COVID-19 Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33443537" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33662103" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307657" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cardiovascular magnetic resonance with parametric mapping in long-term ultra-marathon runners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160404" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31080228" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impact of Myocardial Fibrosis on Left Ventricular Function Evaluated by Feature-Tracking Myocardial Strain Cardiac Magnetic Resonance in Competitive Male Triathletes With Normal Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332151" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3455232" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Myocarditis. A histopathologic definition and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267502" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35404682" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402155" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Multiorgan and Renal Tropism of SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32787909" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172546" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : [A pathological report of three COVID-19 cases by minimal invasive autopsies].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32085846" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pathological findings of COVID-19 associated with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32275742" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : COVID-19 Autopsies, Oklahoma, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32275742" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : COVID-19 Autopsies, Oklahoma, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291399" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730555" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32968776" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35377503" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35132265" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Long-term cardiovascular outcomes of COVID-19.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
